Background The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein (ChAd3-EBO-Z). We aimed to investigate the safety, tolerability, and immunogenicity of ChAd3-EBO-Z in Malian and US adults, and assess the eff ect of boosting of Malians with modifi ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other fi lovirus antigens (MVA-BN-Filo).
Introduction
By August 2014, the burgeoning west African Zaire Ebola virus epidemic, which began in rural Guinea and spread to adjacent Liberia and Sierra Leone, 1 was accelerated by transmission in crowded urban slums. Health-care and other front-line workers accounted for about 5-10% of deaths, and ensuing absenteeism weakened curative and preventive services. 2, 3 Absence of licensed anti-Ebola virus treatments or vaccines to combat the epidemic contributed to a public health calamity in the world's least developed region. 4 A glimmer of hope came from two Ebola vaccines in development that protected nonhuman primates (NHPs) against lethal challenge with Ebola virus. [5] [6] [7] [8] One vaccine, based on a replicationdefective chimpanzee adenovirus 3 vector expressing Zaire Ebola virus glycoprotein (ChAd3-EBO-Z), 9 had never been given to human beings.
In this report, we describe the accelerated clinical development programme that investigated the safety, tolerability, and immunogenicity of ChAd3-EBO-Z at four diff erent doses in Malian adults and two diff erent doses in US adults. Because fi ndings from studies 9 in
NHPs have shown that both immunogenicity and duration of high-level protection against challenge can be extended by administration of a dose of modifi ed vaccinia Ankara (MVA)-encoding Zaire Ebola virus glycoprotein, we sought to assess a heterologous booster in humans primed with ChAd3-EBO-Z. We therefore also describe the eff ect of boosting of Malians with a heterologous vector, MVA expressing Zaire Ebola virus glycoprotein and other fi lovirus antigens (MVA-BN-Filo).
Methods

Study design and participants
A phase 1b, open-label and double-blind, dose-escalation trial of ChAd3-EBO-Z was initiated at the Center for Vaccine Development (CVD)-Mali, Bamako, Mali, in adults 18-50 years of age, recruited from six hospitals and health centres. A phase 1, single-blind, randomised trial of ChAd3-EBO-Z was also initiated at the CVD in Baltimore, Maryland, USA, in participants aged 18-65 years, recruited from the University of Maryland medical community and the Baltimore community. Full inclusion and exclusion criteria are listed in the appendix.
Research in context
Evidence before this study The outbreak of Zaire Ebola virus disease in west Africa in 2014-15 was unparalleled in the morbidity and mortality burden that it evoked, its involvement of health-care and front-line workers, and the intensive transmission documented within urban slums and rural populations. Stakeholder meetings at WHO in August and September, 2014, concluded that clinical development of candidate vaccines to prevent Ebola virus disease should be accelerated. As of mid-August, 2014, one promising candidate, replication-defective chimpanzee adenovirus 3 vector expressing Zaire Ebola virus glycoprotein (ChAd3-EBO-Z), which highly protected non-human primates (NHPs) against lethal challenge with virulent Ebola virus, had not yet been given to human beings. On Aug 30, 2014, and again on July 31, 2015, we searched PubMed for publications (no language or date restrictions) using various combinations of the terms "Ebolavirus", "vaccine", "Ebola", "clinical trials", "phase 1 clinical trials", "non-humanprimates", "non-clinical trials", "chimpanzee adenovirus", "adenovirus vector vaccines", and "Modifi ed Vaccinia Ankara vector". We focused on studies published since 1995, but included older reports where relevant. As of July 31, 2015, only two clinical trials had been published of ChAd3-EBO-Z, one as a bivalent vaccine (1:1 mix with replication-defective chimpanzee adenovirus 3 vector expressing Sudan Ebola virus glycoprotein; US participants) and the other as a monovalent vaccine (UK participants). Both publications represent groups working within the WHO consortium. One publication described preclinical challenge trials in NHPs assessing the short-term (5 weeks after vaccination) and extended (10 months after vaccination) effi cacy of the vaccine.
Added value of this study
This study constitutes the fi rst phase 1 report of monovalent ChAd3-EBO-Z vaccine in west Africans and compares four doses, consisting of 1 × 10¹⁰ particle units (pu), 2·5 × 10¹⁰ pu, 5 × 10¹⁰ pu, and 1 × 10¹¹ pu. 
Implications of all the available evidence
With optimistic extrapolation of these results, a single 1 × 10¹¹ pu dose of ChAd3-EBO-Z might be suffi ciently well tolerated and immunogenic to be eff ective in interruption of transmission of Ebola virus to family members and other close contacts of index patients if used in a ring vaccination tactic after rapid identifi cation of cases. A heterologous prime and boost regimen consisting of a ChAd3-EBO-Z prime followed 2-3 months afterwards by a boost with modifi ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein could confer long-term protection to subgroups (eg, health-care and frontline workers) that need extended protection.
See Online for appendix 
Randomisation and masking
In the US trial, we randomly allocated (1:1) participants to receive 1 × 10¹⁰ viral particle units (pu) or 1 × 10¹¹ pu. The Malian trial was initially designed to test only two doses, 2·5 × 10¹⁰ pu (group 1) and 5 × 10¹⁰ pu (group 2). Because this trial was, to our knowledge, the fi rst time that ChAd3-EBO-Z was given to Africans, and only a few people had received the monovalent vaccine weeks earlier (during the week of Sept 17, 2014) at a trial done at the Centre for Clinical Vaccinology and Tropical Medicine at the University of Oxford 10 (Oxford, UK), and 20 had received bivalent chimpanzee adenovirus 3-vectored Ebola vaccine at the National Institutes of Health (Bethesda, MD, USA; during Sept 2-23, 2014), 11 we vaccinated the fi rst fi ve Malians in staggered progression after the fi rst fi ve Oxford vaccinees. 10 Dose escalation to 5 × 10¹⁰ pu occurred after the data safety monitoring board (DSMB) reviewed 7 day safety data from the recipients of 2·5 × 10¹⁰ pu. When extra doses became available, after protocol approval, we randomly allocated additional Malians (1:1) to receive 2·5 × 10¹⁰ pu (group 3B) or 5 × 10¹⁰ pu (group 3C) in double-blind fashion; open-label groups received 1 × 10¹⁰ pu (group 3A) or 1 × 10¹¹ pu (group 4). In the nested Malian study, we randomly allocated (1:1) Malians primed with ChAd3-EBO-Z to receive MVA-BN-Filo or placebo.
ARB generated randomisation sequences for randomised segments of the Malian trial and for the US trial. In the US trial, randomisation was accomplished through an online database and randomisation software (AdvantageEDC) managed by the EMMES Corporation (Rockville, MD, USA). We used blocked randomisation for both the Malian (block size of six) and US (block size of four) trials, and simple randomisation for the nested Malian study. Clinical staff assigned each enrolled participant a randomisation number from the electronic data entry system that corresponded to a treatment on a computer-generated randomisation list available only to the unmasked study pharmacist (MK) and vaccine administrator.
In the double-blind segments of the Malian trial, study investigators, clinical staff , participants, and immunology laboratory staff were masked. The study pharmacist (MK) and vaccine administrator, who were not involved in other trial assessments, and the study statistician (ARB) were unmasked. In the open-label segments, investigators were aware of dose assignment. In the US trial, study investigators were not masked to study allocation, but participants were masked to the dose of vaccine that they received.
Procedures
ChAd3-EBO-Z drug substance was manufactured at Advent (Pomezia, Italy), an Okairos (now GlaxoSmithKline) subsidiary, and drug product was vialled at the Vaccine Research Center Vaccine Pilot Plant (Frederick, MD, USA) under contract with the Vaccine Clinical Materials Program, Leidos Biomedical Research (Frederick, MD, USA). The vaccine is a sterile, aqueous, buff ered solution that contains ChAd3-EBO-Z in single-dose vials. We stored vaccine at below -60°C. We derived the doses for Malian participants by adjustment of the volume of vaccine injected, as was done in the Oxford trial, 10 to 110 μL (1 × 10¹⁰ pu), 275 μL (2·5 × 10¹⁰ pu), 550 μL (5 × 10¹⁰ pu), or 1100 μL (1 × 10¹¹ pu). For US participants, we delivered the two doses (1 × 10¹⁰ pu or 1 × 10¹¹ pu) in 1·0 mL volume. We gave single doses of vaccine intramuscularly. We injected vaccines into the non-dominant arm triceps.
MVA-BN-Filo vaccine, which encodes Zaire Ebola virus and Sudan Ebola virus glycoproteins, Marburg virus glycoprotein, and Tai-Forest Ebola virus nucleoprotein, was manufactured by Impfstoff werk Dessau-Torman (Dessau-Roßlau, Germany), and supplied as a liquid formulation in tris and NaCl in 2 mL vials; each 0·5 mL dose contained 3 × 10⁸ plaque-forming units. MVA-BN-Filo was the only MVA-expressing Zaire Ebola virus glycoprotein that was available to boost the Malian participants in a timely manner and, to our knowledge, represents the fi rst use of MVA-BN-Filo in an African population.
We watched participants for immediate-onset adverse (eg, anaphylactic) reactions for 60 min after vaccination. Follow-up visits were on days 7, 14, 28, 90, and 180 after primary or booster vaccination. We also saw Malians on day 1; we contacted US participants by telephone on day 1. We recorded local reactions daily for 7 days after the vaccination and reported unsolicited symptoms for 28 days after vaccination. We reviewed symptoms at each follow-up visit and collected blood for tests to monitor participants' health status, including a full blood count, urea and electrolyte measurements, and liver profi le. We did severity grading of adverse events (AEs) and assignment of causal relation of unsolicited AEs according to predefi ned criteria in the study protocols.
We measured plasma IgG responses to glycoproteins of Zaire Ebola virus (all participants) and Sudan Ebola virus (Malian 1 × 10¹¹ pu recipients only) with ELISA. 12 We expressed chimpanzee adenovirus 3-neutralising and adenovirus 5-neutralising antibodies as inhibitory concentration 90 reciprocal titres. 13 We quantifi ed Zaire Ebola virus glycoprotein-specifi c T-cell responses with intracellular cytokine staining. 11, 14 We stimulated cryopreserved peripheral blood mononuclear cells obtained at 0 weeks, 2 weeks, and 4 weeks after ChAd3-EBO-Z vaccination and 0 weeks, 1 week, 2 weeks, and 4 weeks after MVA-BN-Filo boost with overlapping peptide pools for Zaire Ebola virus glycoprotein (Z1 and Z2). We then quantifi ed memory CD4 and CD8 T cells (defi ned by CD45RA and CCR7 expression patterns) producing interleukin 2, interferon γ, or tumour necrosis factor α (TNFα). 11, 14 We deemed responders participants with CD4 or CD8 responses to any peptide pool (measured by interleukin 2, interferon γ, or TNFα) after vaccination, as described elsewhere.
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Outcomes
The primary outcome was safety, measured with actively (solicited-ie, sought by investigators) collected data for AEs for 7 days after vaccination. The secondary outcome was immunogenicity, assessed with ELISA for antibody responses and an intracellular cytokine staining assay for T-cell responses. We measured baseline antivector antibodies using neutralisation assays. A full list of primary and secondary outcomes is given in the appendix.
Statistical analysis
The sample size of 91 for the Malian trial balances the need to avoid exposure of a large group to an unknown risk with the need for data from an adequate sample. We based group sample sizes on availability of study product. This sample size should allow establishment of the magnitude of AEs, rather than obtaining of signifi cance for diff erences between groups. A scarcity of vaccine doses and the desire to study the safety and immunogenicity of a range of dose levels drove sample sizes in the nested trial. In the US trial, the study design was phase 1 dose escalation based on a target accrual of 20 adult participants divided equally between two dose groups.
We reported ELISA antibody responses to Zaire Ebola virus glycoprotein as geometric mean titre (GMT), with 95% CIs. We defi ned positive responses as signifi cant (α=0·05) increases in log-ELISA from baseline, with use of paired t tests. 11 We used Fisher's exact tests for between-group comparisons of proportions of subjects with positive responses or for responses of more than reference values, Student's t tests for the magnitude of the antibody response after log transformation, and Wilcoxon tests to compare the magnitude of T-cell responses or non-normally distributed antibody titres. Tests were two-sided, without multiple comparisons adjustment. We used McNemar's tests to assess whether CD4-positive and CD8-positive T-cell responses occurred in the same or diff erent participants. We analysed associations between antibody and T-cell responses with Spearman's correlation. We fi tted a linear regression model to assess associations of prime-boost interval and priming ChAd3-EBO-Z dose with postboost ELISA response. We analysed and displayed T-cell intracellular cytokine staining data with SPICE 5.3.5. 15 We used SAS 9.3 for other analyses. Analyses were per protocol, but no participants were randomly allocated but not vaccinated and no participants received a product diff erent from their randomisation assignment.
Clinical trial monitoring was provided by CVD-Mali and CVD monitors. A DSMB furnished independent oversight for the Malian trial, whereas a protocol review safety team oversaw the US trial. Both trials are registered with ClinicalTrials.gov, numbers NCT02231866 (US) and NCT02267109 (Malian).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Oct 8, 2014, and Oct 23, 2014, 20 (22%) participants (group 1) in Mali received 2·5 × 10¹⁰ pu of ChAd3-EBO-Z, and between Nov 4, 2014, and Nov 6, 2014, we vaccinated a further 20 (22%) participants (group 2) with 5 × 10¹⁰ pu (fi gure 1). Shortly after enrolment of groups 1 and 2 began, 40 additional doses of ChAd3-EBO-Z vaccine became available for use in Mali. Accordingly, after ethical committee approvals and DSMB concurrence, on Nov 10, 2014, we vaccinated ten (11%) additional participants (group 3A) with a dose of 1 × 10¹⁰ pu, thereby providing a low-dose group for comparison. Between Nov 13, 2014, and Nov 15, 2014, we randomly allocated 30 (33%) additional participants (15 [16%] to each group) to receive a dose of either 2·5 × 10¹⁰ pu (group 3B) or 5 × 10¹⁰ pu (group 3C), with double-blind clinical follow-up. Finally, 11 additional doses became available for the Mali trial; with ethical approval of the amended protocol and DSMB Because of the small number of doses of MVA-BN-Filo available, 56 (62%) of the 91 Malians primed with ChAd3-EBO-Z were deemed eligible for the nested trial, in which we randomly allocated them to receive MVA-BN-Filo or placebo. Eligible participants came from groups 1, 2, 3A, and 4: 15 (27%) of 20 participants from group 1 (we excluded the fi rst fi ve vaccinees because they had received their vaccine several weeks earlier than the remaining 15 had because the safety data from these fi rst fi ve participants were reviewed before further vaccinations took place); the 20 (36%) participants from group 2; the ten (18%) participants from group 3A; and the 11 (20%) participants from group 4. The 29 (one was lost to follow-up after day 7) additional vaccinees who had been randomly allocated to receive 2·5 × 10¹⁰ pu (group 3B) or 5 × 10¹⁰ pu (group 3C) were ineligible because the dose that they had received was still masked. We had insuffi cient time to reprogram electronic data capture to accommodate random allo cation of a secondary subgroup while preserving masking of the priming dose. Between Feb 9, 2015, and Feb 16, 2015, we enrolled 52 (93%) of these 56 eligible participants (three declined to participate and one was medically ineligible based on cardiac screening criteria), representing all four ChAd3-EBO-Z doses and a fairly tight range of intervals (79-111 days) since priming immunisation with ChAd3-EBO-Z, who we randomly allocated to receive MVA-BN-Filo (27 [52%] participants) or saline placebo (25 [48%] participants), followed up clinically in doubleblind fashion.
Analysis of viral titre in vials from the vaccine lot used in the clinical trials showed 1·0 × 10¹¹ pu/mL when tested at the National Institutes of Health (Bethesda, MD, USA) and 9·1 × 10¹⁰ pu/mL when tested at the Jenner Institute, University of Oxford (Oxford, UK). Table 1 summarises participants' demographic and other characteristics; all Malians were health-care and frontline workers. Table 2 summarises the frequency and severity of solicited AEs (unsolicited-ie, off ered voluntarily by participants-AEs described in appendix), by dose, for 7 days after ChAd3-EBO-Z vaccination or MVA-BN-Filo booster (primary outcome). Most AEs were mild, with no unexpected serious adverse reactions suspected. One (1%) serious AE in Mali (tuberculous peritonitis; received 2·5 × 10¹⁰ pu) was unrelated to vaccine. The predominant solicited AE was fever, occurring in seven (8%) of 91 Malian (fi ve [5%] received 5 × 10¹⁰ pu and two [2%] received 1 × 10¹¹ pu) and four [20%] of 20 US (all received 1 × 10¹¹ pu) participants; ten of 11 fevers resolved by 24 h after vaccination and none persisted for longer than 24 h. One (1%) fever of 37·6°C occurred in a Malian volunteer on day 2 after vaccination (5 × 10¹⁰ pu), but still resolved within 24 h. One (1%) Malian (5 × 10¹⁰ pu) and two (10%) US (1 × 10¹¹ pu) vaccinees had fevers with temperatures higher than 38·5°C, accompanied by systemic symptoms (eg, fatigue, myalgia, arthralgia, headache, chills, or nausea). The appendix summarises laboratory abnormalities noted up to day 28. Most episodes (ten of 11) of the most frequent abnormality, lymphopenia, occurred on day 1 after vaccination and self-resolved. In the Malian participants, we noted single cases of moderate (109 × 10⁹/L; 5 × 10¹⁰ pu) and severe (63 × 10⁹/L; 2·5 × 10¹⁰) asymptomatic thrombocytopenia on day 1 after vaccination that resolved by day 7.
Malian adults US adults
Phase 1b trial Nested booster study Phase 1 trial AEs were uncommon in the 27 participants boosted with MVA-BN-Filo. By day 7, the most common local reactions were injection-site pain or tenderness (table 2) . Two (7%) participants boosted with MVA-BN-Filo developed mild fever and associated injection-site pain, mild myalgia, headache, and fatigue. Thick smears for malaria parasites were negative, and both were well by day 3. Other AEs noted up to day 28 are summarised in the appendix. Of 25 participants allocated to placebo booster, one (4%) had an isolated mild fever of 37·9°C.
We measured plasma IgG responses to Zaire Ebola virus glycoprotein with ELISA and compared them with titres that conferred protection in NHP effi cacy trials (secondary outcome).
5 Table 3 and the appendix display the proportion of ChAd3-EBO-Z vaccinees in each group who showed serological responses by day 28, and the GMT. We noted high serological response rates for all dose groups, but GMT was signifi cantly higher in recipients of 1 × 10¹¹ pu than in those given low doses (1 × 10¹⁰ pu, 2·5 × 10¹⁰ pu, and 5 × 10¹⁰ pu). The proportion of Malian vaccinees with day 28 reciprocal titres of 500 or higher, 1000 or higher, or 1500 or higher was signifi cantly higher in recipients of the high dose than in those given low vaccine doses ( Data are n (%). The maximum solicited local and systemic reactogenicity symptoms are depicted through to day 7 after vaccination. pu=particle units. ChAd3-EBO-Z=replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein. MVA-BN-Filo=modifi ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other fi lovirus antigens. *Local adverse events were pain, erythema, induration and swelling, pruritus, and warmth. We noted one episode of mild induration and swelling in a Malian participant (1 × 10¹¹ pu). We recorded no erythema events. †Signs or symptoms that were not collected. antibody persisted at a much higher level in recipients of the high dose of ChAd3-EBO-Z than in those of the low doses (appendix).
The participants in the booster study did not diff er from the non-boosted participants in terms of baseline characteristics (table 1) was similarly signifi cant (geometric mean-fold increase of 33·6 [22·8-49·6]; p<0·0001). The fi ve Malian participants who received 1 × 10¹¹ pu of ChAd3-EBO-Z and were subsequently boosted with MVA-BN-Filo off ered an opportunity to assess whether ChAd3-EBO-Z had primed these individuals to mount accelerated serological responses to heterologous Sudan Ebola virus glycoprotein following the boost. 1 week after the boost, four (80%) of these fi ve participants exhibited serological responses to the Sudan Ebola virus glycoprotein (appendix). By contrast, only one (20%) of these fi ve showed a minimum serological response to the distantly related (diff erent genus) Marburg virus glycoprotein after the boost (data not shown).
The durability of the antibody response to Zaire Ebola virus glycoprotein after administration of high-dose (1 × 10¹¹ pu) ChAd3-EBO-Z alone was assessed in the fi ve recipients of this dose who subsequently received saline booster and provided plasma specimens 180 days after the boost-ie, 259 days after priming (secondary outcome, appendix). Even after 259 days, we noted only a very shallow slope of decay of antibody titres, showing impressive longevity of the antibody response after administration of a single high dose of ChAd3-EBO-Z.
The appendix shows the progressive fl ow cytometry gating strategy used to enumerate antigen-specifi c T cells. T-cell responses to primary immunisation with ChAd3-EBO-Z and after MVA-BN-Filo boosting are summarised in the appendix (secondary outcome). T-cell responses after priming were slight and of small magnitude: 15 (31%) of 49 participants showed either positive CD4 or CD8 responses after priming with ChAd3-EBO-Z, including eight (16%) who mounted measurable CD8 T-cell responses and 11 (22%) who showed CD4 T-cell responses. We noted a strong association between CD4 and CD8 responses in individual participants, except at 7 days after the MVA-BN-Filo boost,
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Data are n (% [95% CI]) or mean (95% CI). This table with comparisons with other studies is provided in the appendix. ChAd3-EBO-Z=replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein. MVA-BN-Filo=modifi ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other fi lovirus antigens. pu=particle units. PFU=plaque-forming units. *One participant did not provide a blood specimen on day 7 and one did not provide one on day 28. McNemar's test p=0·0082). Cell-mediated immunity responses after priming with ChAd3-EBO-Z were stable and long-lived, as shown over time for the 25 participants primed with ChAd3-EBO-Z who later received a placebo booster. By contrast, of the 27 participants boosted with MVA-BN-Filo, we noted high-magnitude postboost CD4 and CD8 responses in 23 (85%) participants (appendix). Similar to after priming, we noted a high degree of concordance between participants who showed both CD4 and CD8 responses. Most Zaire Ebola virus glycoproteinspecifi c CD8 memory T cells were multifunctional, producing both interferon γ and TNFα, or all three cytokines (interferon γ, TNFα, and interleukin 2); 25% of CD8 T cells were interferon γ single-positive.
Discussion
Our results identifi ed the ChAd3-EBO-Z dose for largescale manufacture of the formulation slated for phase 2 and 3 trials in Africa. A single 1 × 10¹¹ pu dose of ChAd3-EBO-Z elicited strong antiglycoprotein antibody responses in all participants. Glycoprotein-specifi c antibodies elicited by adenovirus 5 and chimpanzee adenovirus 3-vectored vaccines constitute a nonmechanistic correlate of protection against otherwise lethal Ebola virus challenge to NHPs, 5, 9, 16 although T cells seem key in mediation of protection conferred by adenovirus-vectored and DNA Ebola vaccines. 5, 17 Of NHPs immunised with adenovirus 5-vectored Ebola vaccine and challenged about 1 month later, 5, 9 animals that attained reciprocal titres of 1000 or higher (with use of ELISA as described by Sullivan and colleagues 5 ) showed 77% vaccine effi cacy against death. Similarly, NHPs that were vaccinated with single-dose chimpanzee adenovirus 3-vectored Zaire Ebola virus vaccine and attained reciprocal titres of 967 or higher were 100% protected against lethal challenge at 5 weeks. 9 Thus, the fi nding that 90·9% of Malian recipients of 1 × 10¹¹ pu attained reciprocal titres of 1000 or higher is encouraging, generating optimism that this vaccine dose might confer high-level protection to vaccinated human beings in the fi eld, at least in the short term. Many believe that the level of infective inocula to which humans are naturally exposed is much less than that of parenteral inocula given to NHPs. If so, ChAd3-EBO-Z could prove useful for diminishing of transmission in defi ned target groups in future Ebola outbreaks. In NHPs, Zaire Ebola virus glycoprotein-specifi c CD8 memory T cells expressing both interferon γ and TNFα were associated with short-term protection (5 week challenge) after one dose of ChAd3-EBO-Z, whereas CD8 memory T cells positive for all three cytokines after booster with MVA-BN-Filo were associated with extended protection (10 month challenge). 9 Subpopulations at high risk of transmission of Ebola virus in Africa consist of two distinct categories. The fi rst consist of family members, neighbours, and other close contacts with people with confi rmed Ebola cases. The second includes health-care and other front-line workers, and people who perform ritual funeral practices for patients who have died from Ebola. Highcoverage, concentric, single-dose containment ring vaccination with immunogenic Ebola vaccines for people in and around the households of people with index Ebola cases could diminish transmission between family members, neighbours, and known contacts, as was achieved with the surveillance and containment strategy that interrupted smallpox transmission in west Africa. 18, 19 For reactive vaccination to successfully contain Ebola virus disease outbreaks, a logistically practical, single-dose regimen that confers high-level effi cacy (even if in the short term) and enables high coverage is needed. The precedent for this strategy was established with the replicating recombinant vesicular stomatitis virus vector expressing Zaire Ebola virus glycoprotein (rVSV-ZEBOV) vaccine in a phase 3 fi eld trial of effi cacy in Guinea. 20 Within a few days of laboratory confi rmation of an Ebola case, a cluster of all contacts and of their contacts was defi ned, and the cluster was randomly allocated to either ring vaccination of consenting contacts around the case to begin immediately or only after a 21 day delay. 20 The primary per-protocol analysis, which compared the incidence of laboratory-confi rmed Ebola in eligible vaccinated contacts in immediate ring vaccination clusters with that in those in delayed ring vaccination clusters, was limited to confi rmed cases that had an onset of illness 10 days or longer after randomisation. Contacts of confi rmed cases were signifi cantly protected if ring vaccination with rVSV-ZEBOV was begun immediately rather than after a 21 day delay. 20 We expect that if ring vaccination was used with high-dose ChAd3-EBO-Z, the vaccine would be similarly eff ective.
A comparison would be interesting of the ELISA antibody responses to Zaire Ebola virus glycoprotein shown by the Malians who received 1 × 10¹¹ pu of ChAd3-EBO-Z with those of Africans who received 2 × 10⁷ plaque-forming units of rVSV-ZEBOV, as used in the Guinea ring vaccination fi eld trial. 20 So far, no data have been published for immune responses with this dose in Africans to allow a comparison. Data exist for serological responses of participants in Gabon and Kenya who received a dose of rVSV-ZEBOV one log lower than those in the Guinea fi eld trial; however, the ELISA methods of measurement of antiglycoprotein were diff erent to those used to obtain the data in the Malian trial described in this report. 21 Publication of results of the phase 2 safety and immunogenicity component of the Partnership for Research on Ebola Vaccines in Liberia trial (NCT02344407) might provide data for this point.
Health-care, front-line, and funeral workers who have repetitive exposures to Ebola for extended periods need a vaccination regimen that confers more durable protection than what is expected to be derived from ChAd3-EBO-Z alone (at least on the basis of NHP studies). 9 Fortunately, accessibility of these individuals makes delivery of a complex vaccination regimen (two spaced doses of two diff erent vaccines) feasible. Accordingly, boosting of front-line workers with heterologous MVA vector expressing Ebola virus glycoprotein could extend the duration of high-level protection, as was noted in NHPs. 9 Antibody and T-cell responses of Malians boosted with MVA-BN-Filo show its powerful boosting capacity.
When these trials began, the scarcity of vaccine doses constrained trial design options. Some consortium partners proposed maximising the potential number of doses with testing of low doses containing 1 × 10¹⁰ pu, 2·5 × 10¹⁰ pu, and 5 × 10¹⁰ pu. 10 Results with a chimpanzee adenovirus 3-vectored hepatitis C vaccine with use of such doses provided a rationale. 22 Other partners argued for testing of two widely separated doses (1 × 10¹⁰ and 1 × 10¹¹ pu) as a starting point to guide further studies. 11 In this study, we tested all four doses of ChAd3-EBO-Z, once suffi cient vaccine doses became available. This strategy acknowledged the possibility that west Africans, diff ering in genetic background, nutritional state, socioeconomic level, and past exposure to adenoviruses and other pathogens, might mount immunological responses distinct from those of consortium participants from Europe and North America who were 80-90% white and living in affl uence. This strategy proved fortuitous because we documented immunological superiority of 1 × 10¹¹ pu to other doses. Importantly, adverse reactions were uncommon at this dose. No Malians and only two of ten US recipients of 1 × 10¹¹ pu had fever with a temperature of 38·6°C or higher, and none had one with a temperature of 39·6°C or higher. Short-lived fevers will not interfere with ring vaccination.
The results reported in this study paved the way for phase 2 trials in adults (PACTR201504001092179) and children (EudraCT 2014-004714-28) and for a phase 3 effi cacy trial in Guinea with the 1 × 10¹¹ pu dose of ChAd3-EBO-Z to follow completion of testing of VSV-ZEBOV in the Ebola ça Suffi t trial. 23 The partners that collectively managed the fi eld trial operation in Guinea decided to proceed with a second round of testing, and ChAd3-EBO-Z was the vaccine selected on the basis of diff erent criteria, which were an acceptable safety profi le, induction of appropriate immune responses in human beings, protection of NHPs, and the timely availability of suffi cient vaccine doses. However, evidence of effi cacy noted with VSV-ZEBOV in the fi eld trial in Guinea led the DSMB for that trial to decline a switch to assessment of ChAd3-EBO-Z vaccine in the same study design of immediate versus delayed ring vaccination of contacts surrounding cases and instead to continue ring vaccination with VSV-ZEBOV, but only with use of immediate ring vaccination after confi rmation of cases; the delayed ring vaccinations that provided the comparator to estimate vaccine effi cacy were discontinued. Thus, the effi cacy trial transitioned to an assessment of the practicality and logistics of immediate ring vaccination as a control measure used in a west African setting. Indeed, since that DSMB decision, too few cases of Ebola have been confi rmed in Guinea to have an effi cacy evaluation and, in midSeptember, 2015, Guinea had the fi rst Ebola-free week since the previous 12 months. 24 The timeframe in which the ChAd3-EBO-Z vaccine progressed from preclinical status to a phase 1b trial in Mali was astoundingly short. Ethics committees and the DSMB did their reviews and regulatory authorities arranged vaccine importations rapidly. The fi rst vaccination occurred on Oct 8, 2014 (less than 2 months after the consortium assembled), the last participant was vaccinated on Nov 26, 2014, and the last day 28 blood was drawn on Dec 24, 2014. This short timeframe included obtaining of approvals for several changes in the size and design of the trial as further doses of vaccine became available.
MVA-BN-Filo booster vaccine given 11-16 weeks after priming with ChAd3-EBO-Z was well tolerated and powerfully immunogenic in elicitation of both anamnestic antibody responses and robust multifunctional CD4 and CD8 memory T-cell responses. On the basis of data from NHP challenges, 9 ChAd3-EBO-Z prime followed by boost with MVA encoding Zaire Ebola virus glycoprotein would be the preferred regimen for immunisation of front-line workers who need long-lived, high-level protection against repetitive exposures. Nevertheless, complexities exist from the perspective of immunisation programmes in procural and delivery of a two-dose schedule with two diff erent vaccines.
This study has limitations. Like other phase 1 trials of Ebola vaccines in Africa, 21, 25 our study had an underrepresentation of women. Also, our study would have been improved if more Malian participants could have received the 1 × 10¹¹ pu dose of ChAd3-EBO-Z than the number that did receive that dose in this study, had more doses been available. Similarly, the small number of doses of MVA-BN-Filo available limited the size of the nested booster study. Finally, our absence of access to a monovalent MVA expressing only Zaire Ebola virus glycoprotein prevented us from also studying that product in the booster study.
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